131I Metaiodobenzylguanidine Therapy of Pheochromocytoma

131I间碘苄胍治疗嗜铬细胞瘤

• 批准号: 6659607
• 负责人: Karel Pacak
• 金额: --
• 依托单位: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6659607
• 关键词: apoptosis; combination cancer therapy; cytotoxicity; drug screening /evaluation; endocrine neoplasm; growth inhibitors; iodine; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer radionuclide therapy; neoplastic growth; pheochromocytoma; radiosensitizer

Pheochromocytomas are tumors of chromaffin cells that synthesize and secrete catecholamines. This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-metaiodobenzylguanidine (131I-MIBG), and in particular tests whether pre-treatment "sensitization" increases the efficacy of 131I-MIBG treatment in reducing the size and number of tumors and the tumor burden. The central hypothesis is that in patients with malignant pheochromocytoma, treatment with 131I-MIBG destroys tumor cells and thereby decreases the size and number of tumors and the tumor burden; and that the "sensitization" procedures augment the effectiveness of 131I-MIBG. This new protocol still needs some clarifications from the FDA, therefore, no patients have been enrolled into the study so far.

嗜铬细胞瘤是合成和分泌儿茶酚胺的嗜铬细胞的肿瘤。本项目检测131i -甲氧十二苄基胍（131I-MIBG）放射毒性治疗恶性嗜铬细胞瘤的疗效，特别是检测治疗前“致敏”是否增加了131I-MIBG治疗在减少肿瘤大小、数量和肿瘤负担方面的疗效。中心假设是，在恶性嗜铬细胞瘤患者中，使用131I-MIBG治疗可破坏肿瘤细胞，从而减少肿瘤的大小和数量，减轻肿瘤负担；“增敏”程序增强了131I-MIBG的有效性。这项新方案仍需要FDA的一些澄清，因此，到目前为止还没有患者被纳入这项研究。